NCT06902987View on ClinicalTrials.gov

Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Crohn's DiseasesActive Anal FistulaUpadacitinib
Interventions
DRUG

Upadacitinib

Enrolled patients received oral upatinib treatment with a conventional induction dose of 45mg/d for 12 weeks, followed by a maintenance dose of 15m/d or 30mg/d

Trial Locations (1)

510000

RECRUITING

Sixth afflicated of Sun-yat sen university, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER